


Review

In Ovo Vaccination Technology: An Alternative Approach to Post-Hatch Vaccination in Modern Poultry Operations

Wafaa A. Abd El-Ghany 

Poultry Diseases Department, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt; wafaa.soliman@cu.edu.eg; Tel.: +20-01224407992

Abstract: Poultry production systems are usually exposed to important infections that could be prevented by vaccination programs. Conventional methods of vaccination such as drinking water; spray, eye, or nose inoculation; and injection are usually given after hatching and have many disadvantages. Therefore, there is a great need for searching of alternative ways for vaccination process. In ovo vaccination technology is now regarded as an alternative approach to post-hatch vaccination in modern poultry operations. This technique is effective, fast, provides uniform vaccine dosing and delivery, is suitable for massive production, and reduces labor costs. Routine in ovo vaccination is applied during the late stage of embryonic development between days 17.5 and 19.25 of egg incubation. The best route of inoculation of the vaccine is in the amniotic fluid or in the embryo's muscles, without causing any hatchability or chick quality losses. Accordingly, the inoculation site, the age of the embryos and breeders, presence of maternal antibodies, and the sanitation of equipment's and the environment during the vaccination process affect the efficiency of the in ovo vaccination technique. In ovo vaccination technology is currently applied for vaccination against several economically important viral diseases such as Newcastle, infectious bursal disease, Marek's disease, infectious laryngotracheitis, infectious bronchitis, avian influenza, and avian metapneumovirus. Moreover, vaccines used for prevention of mycoplasmosis and coccidiosis could be applied in ovo instead of in post-hatching application. It can be concluded that in ovo vaccination is a rapidly growing trend of vaccine technology, and it can replace post-hatching vaccination conventional methods.



Academic Editors: Seyed Ali Ghorashi and Vincenzo Cuteri

Received: 4 November 2024

Revised: 19 December 2024

Accepted: 27 December 2024

Published: 30 December 2024

Citation: Abd El-Ghany, W.A. In Ovo Vaccination Technology: An Alternative Approach to Post-Hatch Vaccination in Modern Poultry Operations. *Microbiol. Res.* **2025**, *16*, 7. <https://doi.org/10.3390/microbiolres16010007>

Copyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: bacterial; in ovo vaccination; parasitic; poultry; technique; viral

1. Introduction

Poultry industry is exposed to variety of stressors and disease conditions that drastically affect production. Therefore, the vaccination of birds is considered a way for reducing disease severity, enhancing bird health, protecting the poultry industry, and providing the consumers with safe meat and eggs [1]. Conventional post-hatch vaccination techniques, including drinking water, spray, injection, or feed, may result in vaccine delivery failure and poor vaccine efficacy [2]. Thus, these techniques, where possible, are being replaced by in ovo vaccination technology, which is more effective and faster and provides a more uniform virus vaccine dose and delivery [3]. Besides, this technique is suitable for a large-scale or massive poultry production system, with a reduction in labor costs and worker's involvement [4].

In ovo vaccination technology was introduced over three decades ago; however, it is currently used in more than 90% of the commercial hatcheries worldwide, including the United States of America, Europe, and Asia [5]. The first description of this technology

was in 1982 as an efficient method of vaccination against Marek's disease (MD) [6]. The efficiency and success of this form of vaccination may be influenced by many factors, including the timing of the inoculation relative to the stage of embryonic development and the precise site of vaccine inoculation in the developing embryo. Routine *in ovo* vaccination is usually applied between days 17.5 and 19.25 of egg incubation via a direct inoculation in the amniotic fluid or in the embryo's body and without causing any hatchability or chick quality losses [7]. In contrast to other post-hatch vaccination techniques, vaccination at day 18 of embryogenesis reduces the time between early exposure to infectious agents and vaccination [4], which helps in the stimulation of an early chick's resistance and with good protection [8]. The *in ovo* vaccination technique, particularly for living poultry vaccines, has proven successful for preventing different economically significant viral [9–17], bacterial [18–20], and parasitic [21,22] diseases.

In this context, this review article was designed to put a spotlight on *in ovo* vaccination technology regarding the mechanism, affecting factors, advantages, and the role of this trend in controlling some important viral, bacterial, and parasitic diseases of poultry.

2. In Ovo Inoculation Technology (Figure 1)

2.1. In Ovo Vaccination Technique

The technique used for the administration of *in ovo* vaccines is critical. Delivering the vaccine in an incorrect location may result in ineffective vaccination, thus reducing its benefits and entailing severe losses. *In ovo* vaccination is applied when the incubated eggs are transferred from the setter to the hatchery between 17 and 19 days of incubation. At the top of the blunt end of the eggshell, a hole is pierced into the eggshell, and then the egg membrane is punctured using the inoculated needle [23,24]. The vaccine is injected slightly beneath the membranes at the bottom of the air cell [25,26]. Vaccines should be deposited into the extra-embryonic sacs, mainly into the amniotic sac; however, they could also be inoculated in the breast, neck, or shoulder of the embryo [26]. The deposition of the inoculated vaccine in the embryonic tissues or in the extra-embryonic compartment depends on the duration of egg incubation and the needle size.




Figure 1. Mechanism of *in ovo* inoculation technology.

2.2. Risks and Challenges

The needles used should be sterilized after the completion of inoculation and before the following inoculation to avoid cross-infection of the inoculated embryos [19]. Due to congenital biological differences of individual eggs, the vaccine cannot be accurately injected; there is lack of control regarding the needle-hit position. This may affect the growth of the chicken embryo [27,28]. During vaccination, the embryo should be in the hatching position where the head under the right wing and the yolk sac would be completely absorbed. Injections after day 19 of incubation may injure the embryo, resulting

in mortality. However, vaccinations at an earlier age may increase the risk of contamination, compromising the livability and quality of the chicks at hatch. Also, during the direct puncturing of egg membranes, the embryo may be injured, causing reduced hatchability, survival rate, and chick health. Leaving a hole in the egg for few days before hatching, along with poor sanitized hatcheries, enhances poor viability of the hatched chicks due to bacterial or fungal contamination [29].

2.3. Advancements in In Ovo Vaccination Systems

The electromagnetic needle-free in ovo injection automation system has been successfully used for accurate inoculation of embryos in eggs [24]. An automatic multiple-head egg injection vaccination system has been distributed in industries worldwide and replaced the conventional method of post-hatch injections at the hatchery [29]. In this technique, liquid jet pressure can be adjusted to the target embryonic tissue; thus, it replaces the traditional needle-type approach and, in consequence, reduces embryo injury and cross-infection, as well as prevents replacing needles and needle-cleaning steps. The egg injection system permits the inoculation of 20,000–30,000 eggs per hour [25], with inoculation doses of 50–200 microliters of injected vaccine per egg [29].

2.4. Effects on the Embryos

Following vaccination, the embryo swallows the dissolved vaccine in the surrounding fluids, and the gut associated lymphoid tissues begin to react with the antigen of the vaccine [30,31]. Moreover, the embryo's choanal cleft can aspirate the vaccine into the nasal cavity and the respiratory tract [28], where the vaccine antigen can stimulate the nasal and bronchial associated lymphoid tissues. Cloacal sucking of the inoculated substances has also been detected [5].

3. Factors Affecting In Ovo Vaccination Technology

3.1. The Inoculation Site

The inoculation site of the egg differs according to the type of vaccine [27,32]. A precise and accurate inoculation site of the egg is required to obtain an optimal response by the embryo [33].

The air cell, amnion, allantois, yolk sac, and embryo's body are the sites where the vaccine could be injected. The selection of the inoculation site may be affected by the survival of the embryos and their response to the vaccine [3]. It has been reported that vaccine inoculation in the amnion could be absorbed by the embryo prior to hatching [5]. For instance, vaccine deposition into the air cell or allantois did not provide adequate protection of chicks against subsequent MD virus (MDV) challenge [33], while amnion inoculation provided the highest vaccine effectiveness [34]. Moreover, the injection might be made directly into the right breast area of the embryo when embryo around 19 days of incubation. Breast inoculation may be considered usual and acceptable; however, injection into another site of the embryo's body can result in either a lack of vaccine efficacy or damage to the embryo [7]. The protection rates against MDV vaccines were 0%, 28.3%, 94.4%, and 93.9% following inoculation in the air cell, allantoic fluid, amniotic fluid, and embryo's body, respectively [11]. Furthermore, Alqhtani et al. [20] demonstrated that the ts-11 *Mycoplasma gallisepticum* (MG) vaccine strain yielded a better protection rate after injection in the amnion (97.2%) when compared to intramuscular injection (2.8%) of the embryos. Intracranial, intraorbital, or intraabdominal inoculations of embryos are regarded as unsatisfactory and ineffective methods that perhaps cause embryonic death [11,35]. In addition, it has been found that the location of vaccine deposition in eggs can have potential consequences on the immune response of the hatched chick [11,36].

3.2. *The Age of the Inoculated Embryos*

The age of the embryos at the vaccination time plays an important role in in ovo vaccination success. In other words, the timing of in ovo vaccine inoculation should be in synchrony with the stage of embryonic development to achieve the required vaccine outcome [2]. Moreover, an appropriate embryonic development stage allows for selection of the optimum size and position of the embryos for exact and correct vaccine inoculation. Therefore, the late stage of embryogenesis, at approximately 18 days of chickens age, is appropriate due to maturation of the systems, including the immune organs [37] and the best immune response [22,38,39]. No detectable lesions could be observed when inoculating the vaccine to 17- to 19-day-old embryos or older due to the development of protective immunity and resistance, as well as the support of virus replication [28]. Additionally, vaccination at this time has a minimum impact on the hatching rate and it maintains the stable physiological status of embryos. Rapid replication of the infectious bursal disease virus (IBDV) and infectious bronchitis virus (IBV) has been detected in embryos tissues when inoculated on day 18 of their development [40–42].

Early in ovo vaccination may increase the risk of contamination, which compromises the livability and quality of the chicks post-hatching [43]. When the herpesvirus of turkeys (HVT) vaccine was administered in 10- to 12-day-old embryos, the virus was rapidly replicated and caused severe lesions and deaths of the embryos [44]. Similarly, the in ovo vaccination of 13-day-old embryos resulted in higher embryonic mortality compared to vaccination of 18-day-old embryos [8]. Reduced hatchability around an average 1% was observed in hatcheries when in ovo vaccination was applied on day 17 of incubation [29]. In a similar study [7], the results indicated that the in ovo vaccination on day 16 of incubation reduced the hatchability in 4.68% in comparison to the other vaccination days. Furthermore, Williams [45] demonstrated that too-early inoculation of eggs (before day 17.5) might be very invasive, causing embryonic damage, and the vaccination process could be overwhelmed by the high microbial challenge during hatching. However, the ideal time for safe inoculation of the eggs could be from day 17 and 12–14 h of incubation to day 19 and 2–4 h of incubation [45]. On the other hand, the inoculation of eggs after day 19 of age may induce embryo injury and mortality.

3.3. *The Age of Breeders*

The breeder's age may also influence the determination of in ovo vaccination timing [46]. Day-old chicks of old breeders, which were usually subjected to a vigorous vaccination program, presented a lower immunity when compared to chicks of young breeders. However, other studies showed that the antibody titers against IBDV and fowlpox virus (FPV) in day-old chicks and their performance at slaughtering were not affected by the in ovo vaccination time or by the breeder's age [7].

3.4. *The Maternal Immunity*

Maternal immunity may show some adverse effects on the in ovo vaccination technology. In the presence of high titers of maternal antibodies in vaccinated chicks, the vaccine was not able to override immunity, yielding a low vaccination efficiency. For example, maternal immunity can affect the efficiency of in ovo vaccination against certain diseases such as MD. Therefore, developing insensitive vaccines to maternal antibodies or the vaccination of chick embryos on day 18 of development is important to overcome this problem [7].

3.5. *Other Factors*

Other factors, including sanitization of the equipment, aseptic vaccine preparation, and hatchery hygiene, may affect the efficiency of in ovo vaccination technique [35,47].

4. Advantages of In Ovo Vaccination Technology

The in ovo vaccination technique should be easily applied, achieve vaccine efficiency, enhance embryos health, and ensure chick quality [35]. Furthermore, the approach should allow for an even and uniform mass vaccination with a fast vaccine delivery, provide precise inoculation, reduce stressful conditions on chicks, enhance bird welfare, decrease the contamination and the time between hatching and placement on the farm, reduce labor costs, and allow for the application of other biological materials that may influence broiler performance [29,43].

In ovo embryonic vaccination has a positive effect on the chick's immune response. It has been supposed that this technique contributes to reducing the period between early exposure to infectious agents and vaccination [4], which helps to avoid maternal immunity interference and stimulates earlier embryonic immunity [7,33]. By the time of hatching, vaccinated chicks develop a more significant degree of protection in the form of innate and adaptive immunity when compared to vaccinated chicks after hatching [4,35].

5. Application of In Ovo Vaccination Technology Against Some Important Diseases of Poultry (Figure 2)

5.1. Viral Diseases

5.1.1. Newcastle Disease

Newcastle disease is a devastating viral infection that affects most avian species, and it is caused by avian Orthoavulavirus 1 (previously paramyxovirus 1) [48]. Biosecurity measures and widespread vaccination programs have been unable to prevent outbreaks of NDV [49]. Despite the application of extensive NDV vaccination protocols with more virulent vaccines, particularly in endemic countries, outbreaks continue to occur in many areas all over the world [50–52].

The ideal vaccine against NDV should be able to fill the gap and protect chicks in the first weeks of life. Moreover, it should stimulate both cell-mediated and humoral immunity to reduce the replication of virulent field viruses, the shedding rate, and possible horizontal transmission. Living and inactivated vaccines against NDV are commercially available worldwide [53]. Oral or intraocular application of living NDV vaccines provides neutralizing immunity and induces mucosal immunity [54], but some of them may cause some respiratory manifestations and reduce productivity [55]. Though inactivated vaccines induce long-lasting immunity [56], they neither replicate in the host nor elicit strong cell-mediated immunity [54].




Figure 2. Application of in ovo vaccination technology against some important diseases of poultry.

There have been some attempts to develop other methods for NDV vaccination. Vaccination against NDV using a living vaccine in ovo faces many limitations and challenges such as high embryo mortality, the presence of maternal-derived antibodies, and incomplete protection during the early weeks of life [8,57–61]. Low geometric mean titers against

the NDV vaccine have been observed in specific pathogen-free (SPF) chickens vaccinated against IBDV and NDV using in ovo techniques [62]. The best timing of in ovo vaccination against NDV is on day 18 of embryogenesis when the last and third wave of thymus colonization occurs [63]. The study of Ohta et al. [64] showed that in ovo administration of an aluminum hydroxide-adsorbed attenuated NDV vaccine resulted in improved hatchability and survival rate, as well as better antibody responses of protection-level immunity compared to the administration of NDV alone.

There are about 13 recombinant viral vector vaccines against NDV. The first generation consisted of two FPV vectors, followed by six second-generation and five third-generation vaccines incorporating an HVT vector with the fusion (F) protein or the hemagglutinin (HA)-neuraminidase (NA) protein of NDV. Most of these vaccines are administered using an in ovo route [65,66]. A recombinant (rFPV) expressing the F and HA-NA glycoproteins of NDV and chicken type I or type II interferon (IFN) were applied in the eggs of turkeys [67]. They did not affect the hatchability or survival rates, the performance, the weight gain, or the immune response of hatched chicks. A recombinant HVT expressing NDV F protein (rHVT-ND) (Meleagrid alpha herpesvirus 1) has been successfully used for in ovo vaccination against NDV infection in chickens. Despite the fact that a single application of rHVT-ND vaccine provided long-lasting protection against the virulent strain of NDV with no obvious clinical manifestations, it took up to 4 weeks to mount a protective immune response, meaning it cannot be used as a primary vaccine with other rHVT-vectored vaccines and would be expensive to implement [68–70]. Recently, Marcano et al. [17] reported that in ovo vaccination of 19-day-old embryos with a recombinant, live, attenuated NDV vaccine containing the antisense sequence of chicken interleukin 4 (IL-4) (rZJ1*L-IL4R) induced the highest degree of protection against NDV challenge without adverse effect on the survival rate of the hatched chicks. However, the antisense RNA may cause transcriptional interference via different mechanisms, so modulating gene expression by reducing or completely silencing a gene is important [71,72]. A recombinant FPV co-expressing type I IFN, as well as the NDV HA-NA and F proteins, enhanced the protective efficacy of the vaccine against NDV challenge when given in ovo and at hatching [73]. Moreover, a recombinant virus vaccine containing rNDV, rNDV49, and rNDVGu was compared with a living NDV Clone 30 vaccine following in ovo injection [74]. The findings indicated that only one bird from the NDV Clone 30 vaccine group survived for 3 weeks, whereas the survival rate of hatched chicks from other groups receiving recombinant NDV vaccine was between 40% and 80%. Moreover, in ovo administration of an antigen–antibody complexed live B1-La Sota NDV vaccine provided full immunity against phylogenetically distant virulent viruses at an early age in the presence of maternal immunity [75].

5.1.2. Infectious Bursal Disease

Infectious bursal disease is regarded as an important disease of broiler chickens that is caused by the Avibirnavirus genus. Due to the resistant nature of the virus, biosecurity measures and vaccination protocols are routinely used for the prevention of IBDV infection.

The classical live attenuated IBDV vaccines are usually applied in the drinking water, while the vector-based and immune complex vaccines are applied either in ovo or subcutaneously. The immune complex vaccines containing live intermediate plus IBDV strains have been mixed with hyper-immune sera to produce virus–antibody complex vaccines. Application of this type of vaccine in ovo provided good protection against the virulent IBDV challenge even in the presence of high levels of maternal-derived antibodies to the virus [76]. In Spain, a single in ovo immunization of broiler chickens with an immune complex IBDV vaccine induced high and uniform protective immunity between 35 and 51 days of age, with mean antibody titers values ranging between 6.331 and 7.426 [16].

Combining a live IBDV vaccine virus with the immune complex vaccine could be used in ovo or at hatching [77,78], as it can be replicated at the most suitable time and provide active immunity [43,79].

Despite the fact that the presence of high persistent levels of maternal antibodies can protect chicks during the first weeks of life, they can prevent the classical living IBDV vaccines from providing active protection following single or repeated applications. Live IBDV strains might be neutralized or break down through maternal-derived immunity and induce constant damage to the chick's immune response [80]. In four field trials of Ashash et al. [81], a conventional live intermediate plus IBDV vaccine strain and the IBDV MB-1 were applied in maternally immunized embryos and in one-day-old chicks using a subcutaneous route. The findings confirmed that the in ovo application of live IBDV MB-1 vaccine induced full protection of broilers against a very virulent virus challenge at 22 and 36 days of age as indicated by the bursa lesion score, the q polymerase chain reaction, and virus genotyping. Furthermore, in ovo vaccination with an intermediate live IBDV vaccine was found to be able to evoke active immune response and protection of 21-day-old SPF chickens as testified by bursal lesions, the bursal index results after challenge, and vaccine immuno-response [62]. In addition, the study of Lara et al. [82] proved that the inoculation of an intermediate live IBDV vaccine strain in 18-day-old embryos or in day-old hatched chicks derived from vaccinated breeders induced no effect on the feed intake, feed conversion ratio, and weight gain till 40 days of age. Hence, it could be concluded that in ovo vaccination against IBDV did not adversely affect the hatchability or survival of hatched chicks [83]. The immuno-pathogenesis of IBDV following in ovo vaccination using an intermediate live IBDV vaccine strain has been described [84]. The results indicated that inoculation of the living IBDV vaccine in ovo induced faster recovery from bursal lesions and similar protection against virus challenge when compared to post-hatch vaccinated chickens. Recently, Zaheer et al. [85] compared the immuno-pathological effects of in ovo vaccination with a post-hatch vaccination in white Leghorn chicks, and they concluded that in ovo vaccination with live IBDV vaccines provoked protective immunity even in the presence of IBD-specific maternal immunity.

Some previous studies showed the presence of IBDV in the bursa of Fabricius, with bursal lesions after in ovo vaccination with a modified live IBDV [86,87]. In ovo vaccination with a classic or Delaware E variant strains of IBDV produced a 6-day delay in the onset of IBDV infection [88]. However, McCarty et al. [89] revealed that in ovo inoculation of modified live IBDV vaccine infected the bursa of Fabricius in maternal-antibody-negative and maternal-antibody-positive eggs. In addition, in ovo vaccination of antibody-free broiler chickens with modified live IBDV vaccine induced immunity to post-hatching IBDV exposure [62,90].

The efficacy of the in ovo prime-boost vaccination against IBDV using a DNA vaccine followed by a killed-vaccine boost post-hatching in addition to the adjuvant effects of plasmid-encoded chicken IL-2 (ChIL-2) and chicken IFN- γ (ChIFN- γ) in conjunction with the vaccine were tested [91]. The findings revealed that the in ovo DNA vaccination followed by a killed vaccine could completely protect chickens after challenge with very virulent IBDV in terms of the absence of mortality and reduction in both the bursal damage and lesion score. In addition, the addition of ChIL-2 or ChIFN- γ did not enhance the protective immunity. Both IBDV and MDV vaccines could be jointly administered in ovo without interference with each other [29]. The study of Gagic et al. [92] showed that a single in ovo inoculation of a vaccine containing serotypes 1, 2, and 3 of MDV, serotype 1 of IBDV, and a recombinant FPV vaccine with HA-NA and F genes of NDV (rFP-NDV) produced protection against all these viruses. Furthermore, the inoculation of a vaccine containing

serotypes 1, 2, and 3 of MDV and IBDV did not affect hatchability, although the addition of rFP-NDV to the mixture reduced hatchability by 23% to 26%.

It was summarized that vaccination against IBDV using in ovo inoculation technology decreased the stress of bird handling, induced better immune response, and minimized the risks of contamination and disease spreading [93].

5.1.3. Marek's Disease

It has been shown that in ovo vaccination could give greater protection against an early MDV challenge than subcutaneous vaccination at hatching [6]. Since the success of this initial study, the in ovo vaccination technology was developed and distributed worldwide to combat MDV infections [25,29]. However, the exact successful mechanism of in ovo vaccination with HVT has not been fully determined [94].

Early infection with MDV and consequent early immune response and protection against infection were obtained after in ovo vaccination [40]. It has been reported that vaccination against MDV on days 17 and 18 of incubation did not interfere with the immune response, decreased the susceptibility of chicks to the onset of disease lesions, and supported virus replication by the embryos [28]. Similarly, in ovo vaccination against MDV after 18 days of chicken's eggs incubation provoked earlier protection than vaccinations on the first day of life, because the vaccine took up to 8 days to become effective [95]. Chickens given serotype 1 of MDV (CVI988) during embryogenesis showed better protection against virulent MDV challenge than those given MDV CVI988 at hatching, as the virus could be expressed in the embryo to initiate the pre-hatch immunologic response [96]. Regarding other research, Schat [70] reported on immune interference following vaccination with an HVT vaccine in the embryo, wherein antibodies could neutralize a second HVT vector vaccine after hatching. The site of MDV vaccine inoculation in ovo may also affect the protection rate of embryos. In the study of Wakenell et al. [11], the findings showed that when the HVT/SB-1 vaccine was injected in the air cell, allantoic fluid, amniotic fluid, and embryo's body, the protection percentages were 0%, 28.3%, 94.4%, and 93.9%, respectively.

Ricks et al. [29] reported that both IBDV and MDV vaccines could be administered together in ovo with no interference with each other. The in ovo vaccination with a vaccine containing both MDV and IBDV vaccine viruses did not enhance the inhibitory effect of individual viral agents on the humoral and cellular immune competence [92]. In addition, an HVT vector vaccine expressing IL-2 enhanced the protection induced by IBDV and IBV live attenuated vaccines when given via an in ovo route [97]. Moreover, the protective efficacy of in ovo vaccination with rHVT against NDV and MDV in chickens was evaluated with successful results [98].

5.1.4. Infectious Laryngotracheitis

Infectious laryngotracheitis virus (ILTV) is taxonomically classified as Gallid herpesvirus 1 [99], and it is associated with expectoration of bloody exudate, gasping, and asphyxia in chickens [100]. The disease usually generates severe production losses as a result of increased mortality, decreased egg production, loss of body weight, and predisposition to other respiratory pathogens [101].

The prevention of ILTV infection is based on biosecurity measures and vaccination using living attenuated virus vaccines produced in embryonated chicken eggs (ECEs) or tissue culture [102–105]. However, new generations of recombinant viral vector ILTV vaccines containing FPV and HVT as vectors have been developed [106]. Vector vaccines reduce the possibility of viral transmission from one bird to another, in addition to the absence of latent infection after vaccination or reversion of virulence. There are different immunization routes for ILTV vaccines, but the most practical route is in ovo vaccination

with HVT, MDV, or via a GaHV-1 'meq' gene-deleted vector. Vectored ILTV vaccines are now being applied in ovo [107]. It has been documented that in ovo inoculation of recombinant HVT-ILTV was ineffective to break the chain of viral transmission [108]. Vaccinated chickens showed reductions in clinical signs, maintained body weight gain after challenge, and lessened the challenge virus replication in their tracheas at a rate of 52–65%. However, in spite of this reduction, the transmission of challenge virus from rHVT-LT-vaccinated to contact-naive chickens was evident. This study is the first to support that rHVT-LT vaccination did not prevent the spread of the challenge virus to contact birds. Though the study of Johnson et al. [109] indicated that in ovo vaccination with FPV-ILT and HVT-ILT vector vaccines slightly reduced the clinical signs of ILTV, the vaccine did not significantly reduce the replication of the virus in the trachea. In ovo vaccination with either an HVT-ILTV or FPV-ILTV vaccine did not provide as much protection as ECEs-derived vaccines given at 2 weeks of age. In addition, Vagnozzi et al. [107] found that inoculation of the recombinant ILTV vectored vaccines in eggs or subcutaneously at hatching provided more protection and reduction in the severity of clinical signs and virus replication in the trachea when compared to eye drop vaccination of broiler chickens with a living attenuated ILTV vaccine at 14 days of age. Moreover, inoculation of the HVT-ILTV vaccine in ovo resulted in inhalation or swallowing the vaccine from the amniotic fluid of the embryo, and the vaccine could reach the trachea [11], while injection of the vaccine in day-old chicks resulted in deposition and absorption of the vaccine by the tissues and systematic distribution in the blood. The HVT-ILTV vaccine was more efficient than the FPV-ILTV vaccine in alleviating the disease and reducing the challenge virus level when applied either in ovo or subcutaneously in chicks. Moreover, it has been found that reactions to the FPV-ILTV vector vaccine can be obtained when administered at 17.5 to 18 days of embryonic age rather than at 19 days [110].

The safety and efficacy of a novel "glycoprotein J gene-deleted strain of ILTV" were evaluated in broiler chickens following in ovo vaccination at 18 days of embryo age [111], and the results indicated that this method of vaccination was safe and did not affect the hatchability or survivability of the hatched chicks. Moreover, the vaccination of broilers using either in ovo alone or in ovo combined with eye drop routes revealed significant reduction in the signs and the ILTV load post-challenge [111].

The study of Thapa et al. [112] showed that the CpG DNA ILTV vaccine delivered in ovo reduced the pre-hatch viral infection in correlation with the expression of IL-1 β , increased macrophages in lungs, and decreased the mortality and morbidity resulting from ILTV infection post-hatch. Gimeno et al. [113] found that inoculation of the rHVT-ILTV vaccine via inoculation of the amnion at day 18 and day 19 of egg incubation resulted in more virus replication in the spleen, with more detectable glycoprotein I gene transcripts than in subcutaneous inoculation of day-old chicks.

5.1.5. Infectious Bronchitis

Infectious bronchitis is a highly contagious and an acute upper respiratory tract disease in chickens. The disease is caused by a virus that belongs to the genus corona virus and family Coronaviridae [114]. Infection of chickens with IBV induces severe economic losses in terms of drops in egg production and reduction in egg quality layers, as well as poor weight gain and increased mortalities and condemnation rates of broilers [115]. Prevention of the disease depends mainly on the application of both live and inactivated IBV vaccines. However, the emergence of new IBV variant strains [116], the labor, and the costs of vaccine production increase the need for other types of vaccines such as the recombinant DNA types [117].

In ovo vaccination with IBV vaccines has been successfully applied [42,118–121]. The early study of Wakenell et al. [118] revealed that embryos or day-old chicks vaccinated with tissue culture serially passaged IBV vaccines had similar lesions in the trachea, primary and secondary immune responses, and absence of the effector cytotoxic cells to IBV. In addition, Chew et al. [122] studied the effect of the inoculation of live IBV vaccine and attenuated kidney cell culture IBV in 18-day-old embryos, and the results showed that the hatchability rate was significantly lower in the group vaccinated in ovo (27%) than those who received the attenuated virus (45–58%). Moreover, inoculation of the vaccine and the attenuated IBV in day-old chicks with maternal antibodies induced no pathological lesions in the oviduct, and the respiratory signs were seen in 61% and 5% of chicks inoculated with the vaccine in the eggs and at hatching, respectively. In another study [123], hatched chicks from inoculated 17-days-old embryos with eight different strains of IBV that represented seven different serotypes showed strict epitheliotropic nature and wide tissue tropism of the IBV strains in the chicken embryos and the universality of riboprobe.

Broilers that received HVT/SB-1 and HVT plus CVI-988 MDV vaccines either in ovo or at hatching showed better protection rates to IBV challenge than those that received IBV vaccines (Ark and Mass serotypes) at hatching [124]. In addition, MDV vaccines that were inoculated either in ovo or at hatching did not affect the efficiency of the IBV vaccine given by eye drop at hatching. It has been noticed that in ovo vaccination at 18 days of age with the IBV M-41 vaccine could affect the hatchability; therefore, using an automatic injective system capable of handling 60,000 eggs at a time could improve the hatching rate [125].

Vaccination of chickens with the DNA vaccine containing the S1 glycoprotein gene from IBV induced protective immunity against infection [126,127]. Inoculation of this vaccine in ovo or intramuscularly after hatching provided chickens with some protection against clinical signs following homologous virus challenge [120]. Babapoor et al. [117] studied the effect of the in ovo inoculation of a plasmid DNA pTracer-CVM2-IBVS (pCMV-S) vaccine that expresses the immunogenic S glycoprotein genes of the IBV serotype Massachusetts 41 and a recombinant chicken interferon type I alpha (rChIFN) as an adjuvant. The results showed that chicks that received the pCMV-S vaccine had mild signs and were protected at the level of 66%, but those that received a combination of the pCMV-S with 2000 IU or 500 IU of rChIFN revealed protection at levels of 83% and 89% respectively. Furthermore, bolstering the pCMV-S and 500 IU rChIFN inoculated chickens with the live attenuated IBV vaccine indicated significant protection (more than 92%) against IBV challenge. Resiquimod and toll-like receptor 7 ligand agonist delivered in ovo enhanced host responses and produced secretory immunoglobulin, as well as antigen-specific humoral responses against the IBV vaccine [128].

5.1.6. Avian Influenza

Avian influenza virus (AIV) is an enveloped, negative-sense single-stranded segmented RNA virus in the family Orthomyxoviridae [129]. Despite immunization against AIV having been established as one of the most significant control strategies in the poultry production system all over the world, AIV has gone through antigenic drift due to the presence of immune pressure [130]. Therefore, it is difficult to select a vaccine strain that has the potency to face the widely circulating mutants of AIV.

In ovo inoculation of 18-day-old white rock and white Leghorn chicken embryos with oil-emulsion-inactivated NDV or AIV H5N9 vaccines induced acceptable hatchability, seroconversion rates, and protective immunity when prepared with sufficient antigen amounts and proper administration [131]. Many types of AIV vaccines have been studied for in ovo administration, including non-replicating adenovirus vectors expressing hemagglutinin proteins [132–134], attenuated vaccines [135], and recombinant attenuated vaccines [136].

Chicken embryos that received 10^9 infectious units of an adenovirus vector AIV vaccine showed that less than 1% of hatched chickens displayed serum antibody titers by 10 days post-hatching, while the percentage rose to 65% and 85% by 20 and 40 days post-hatching, respectively [133]. A previous study showed that in ovo vaccinated chicken embryos with a recombinant attenuated H5N1 AIV vaccine induced humoral immune response to the H5 protein in 30% of the hatched chickens, and 80% of vaccinated chickens survived post-challenge [136]. Moreover, vaccination of 18-days-old embryos with a live AIV H9N2 vaccine produced higher antibody response at young age and showed better protection upon challenge than eggs inoculated with an inactivated oil emulsion AIV vaccine [137].

It has been reported that the in ovo administration of CpG ODN decreased the replication of H4N6 AIV and IBV in the inoculated eggs [138,139]. Recently, the immune responses in chickens against a beta-propiolactone inactivated H9N2 AIV vaccine after a primary vaccination on embryonic day 18 and a secondary intramuscular vaccination on day 14 post-hatching were detected [15]. Also, the toll-like receptor 21 ligand, CpG ODN 2007, and an oil emulsion adjuvant were included [15]. The secondary vaccine induced antibody-mediated immune responses, and a beta-propiolactone inactivated virus combined with adjuvant provoked cell-mediated immune responses.

5.1.7. Avian Metapneumovirus Infection

Metapneumovirus infection in turkeys is termed as turkey rhinotracheitis in turkeys and swollen head syndrome in chickens.

The vaccination of turkey eggs with avian metapneumovirus subtypes A and B vaccine revealed that the hatched turkey poults showed resistance to the virulent virus challenge [13]. It has been also found that hatched chicks from inoculated eggs with metapneumovirus vaccine showed earlier immunity than day-old vaccinated turkey poults [140]. Inoculation of a living attenuated metapneumovirus vaccine subtype C in the amnion of turkey eggs showed no effect on the hatching rate, and the vaccine virus was able to replicate in the upper respiratory tracts and the lungs of vaccinated birds, along with low histopathological lesions seen in vaccinated birds after challenge with a virulent strain of avian metapneumovirus at 3 weeks old [141]. Moreover, high resistance to the virus replication was observed, which was correlated with a low count of the virus in the upper respiratory tract.

5.2. Bacterial Diseases

Mycoplasmosis

Mycoplasma gallisepticum (MG) is the main cause chronic respiratory disease of chickens an infectious sinusitis in turkeys, with subsequent severe adverse impacts on production worldwide [142]. Affected layers show drastic drops in egg production, and broilers show low growth rates [143,144]. Eradication of the MG infection could be achieved through vaccination, isolation, and biosecurity measures [145]. Commercially available live MG vaccines include an F strain of MG (FMG), a 6/85 strain of MG (6/85MG), and a ts-11 strain of MG (ts-11MG), which have different features and might be used to effectively control and eradicate the field strains of MG. Vaccination against MG is usually applied for pullets before the start of egg production at 9 weeks old through spray, eye drop, wing web, or intramuscular/subcutaneous methods [146,147].

The effects of the in ovo vaccination with the FMG vaccine on layer chick hatchability [148] and post-hatch survivability, immunity, and horizontal transmission were studied [144]. The results revealed that injection of the FMG vaccine in 18-day-old embryonated chickens eggs induced higher embryonic [19,148] and post-hatch [144] mortalities in comparison to control non-injected eggs. The bacterium was detected in the trachea,

mouth, esophagus, yolk sac, and duodenum of 22-day-old chick embryos [148]. However, a significant decrease in the growth rate [148] and depression of the humoral immune response [144] were observed in post-hatching chicks till 6 weeks of age. Furthermore, another study showed that the F strain of MG was horizontally transmitted from vaccinated to unvaccinated layer pullets through direct contact [149]. However, Alqhtani et al. [20] demonstrated that hatched chicks from eggs injected with the ts-11 strain of MG vaccine remained MG-free till 21 days post-hatch, and the vaccine had no impact either on the hemagglutination inhibition titers or on the post-hatch serology of the layers. The timing of the humoral immune response in the layer chicks during the first 4 weeks of age following in ovo vaccination with FMG was evaluated [150]. The results of the previous study indicated early detection of MG antibodies at 7 days of age. Moreover, the in ovo FMG vaccination was more effective in male layer chickens than females.

5.3. Parasitic Diseases

Coccidiosis

Avian coccidiosis is a host, tissue, and immune-specific intestinal protozoan parasitic disease caused by the *Eimeria* species. The disease is associated with high economic losses, including reduced performance parameters, increased mortalities, and high medication costs [151,152]. In addition, coccidiosis is regarded as a major predisposing factor to necrotic enteritis that is caused by *Clostridium perfringens* [153]. In the field, the prevention strategy of coccidiosis is based on using anticoccidial drugs in the feed, as well as living vaccines [154,155]. It is important to mention that the vaccine strains of *Eimeria* are sensitive to anticoccidial drugs.

Live *Eimeria* oocysts vaccines are applied in the early life of chicks to help in the development of immunity against the wild-type *Eimeria* species following oocyst cycling [156]. Live vaccines against coccidiosis could be applied through the in ovo injection of embryos during incubation [157,158]. These vaccines were administered in 18-days-old chick's embryos [159,160]. A living oocysts vaccine containing a mixture of *E. acervulina*, *E. tenella*, and two strains of *E. maxima* was used.

Commercially, the ideal time for in ovo vaccination against coccidiosis is during late embryonic development (between 17.5 and 19.0 days of chick embryonation) at +14 h with a maximum amniotic fluid [3,27]. Moreover, the inoculation of embryos with infective *Eimeria* strain vaccines at 18.0, 18.5, or 19.0 days of embryonation did not effect hatchability or chick quality [2,38,159]. Sokale et al. [22] demonstrated no significant difference in the cycling of coccidiosis following vaccination at 18.5 and 19.0 days of incubation.

Following in ovo inoculation of *Eimeria* oocysts, they were absorbed in the amniotic fluid and remained dormant in the embryo's intestine without occurrence during the life cycle until chick hatching [161]. Weber and Evans [159] reported that the in ovo inoculation of *Eimeria* species oocysts resulted in a shedding peak at approximately 7 days post-hatching.

6. Conclusions

Nowadays, in ovo vaccination is regarded as an alternative approach to the post-hatch conventional vaccination of birds, especially in broiler chickens. It is a rapidly growing trend of vaccine technology. Currently, in ovo vaccinations against some avian viral, bacterial, and parasitic diseases are still under investigation, and there is progress regarding the production of safe and efficient vaccines.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All prepared data are presented in the present article.

Conflicts of Interest: The author provides the publisher with a copyright license, granting the publisher the exclusive right to publish and sell the study findings in whole or in part in any language. The author has no relevant financial or non-financial interests to disclose.

References

- García, M. Current and future vaccines and vaccination strategies against infectious laryngotracheitis (ILT) respiratory disease of poultry. *Vet. Microbiol.* **2017**, *206*, 157–162. [CrossRef]
- Sokale, A.O.; Zhai, W.; Pote, L.M.; Williams, C.J.; Peebles, E.D. Effects of coccidiosis vaccination administered by in ovo injection on the hatchability and hatching chick quality of broilers. *Poult. Sci.* **2017**, *96*, 541–547. [CrossRef] [PubMed]
- Williams, C. In ovo vaccination for disease prevention. *Int. Poult. Prod.* **2007**, *15*, 7–8. Available online: <http://www.positiveaction.info/pdfs/articles/pp15.8p7.pdf> (accessed on 10 September 2024).
- Negash, T.; Al-garib, S.O.; Gruqays, E. Comparison of in-ovo and post-hatch vaccination with particular reference to infectious bursal disease. A review. *Vet. Q.* **2004**, *26*, 76–87. [CrossRef] [PubMed]
- Jochemsen, P.; Jeurissen, S.H.M. The localization and uptake of in ovo injected soluble and particulate substances in the chicken. *Poult. Sci.* **2002**, *81*, 1811–1817. [CrossRef]
- Sharma, J.M.; Burmester, B.R. Resistance of Marek's disease at hatching in chickens vaccinated as embryos with the turkey herpesvirus. *Avian Dis.* **1982**, *26*, 134–149. [CrossRef]
- Fernandes, J.I.M.; Prokoski, K.I.; Oliveira, B.C.I.; Oro, C.S.I.; Oro, P.J.I.I. Evaluation of incubation yield, vaccine response, and performance of broilers submitted to in-ovo vaccination at different embryonic ages. *Braz. J. Poultry Sci.* **2016**, *18*, 55–63. [CrossRef]
- Okwor, G.O.; El-Yuguda, A.; Baba, S.S. Profile of maternally derived antibody in broiler chicks and in-ovo vaccination of chick embryo against Newcastle disease. *World J. Vaccines* **2014**, *4*, 72–80. [CrossRef]
- Ahmad, J.; Sharma, J.M. Protection against hemorrhagic enteritis and Newcastle disease in turkeys by embryo vaccination with monovalent and bivalent vaccines. *Avian Dis.* **1993**, *37*, 485–491. [CrossRef] [PubMed]
- McMillen, J.K.; Cochran, M.D.; Junker, D.E.; Reddy, D.N.; Valencia, D.M. The safe and effective use of fowlpox virus as a vector for poultry vaccine. *Dev. Biol. Stand.* **1994**, *82*, 137–145. [PubMed]
- Wakenell, P.S.; Bryan, T.; Schaeffer, J.; Avakian, A.; Williams, C.; Whitfill, C. Effect of in ovo vaccine delivery route on HVT/SB-1 efficacy and viremia. *Avian Dis.* **2002**, *46*, 274–280. [CrossRef] [PubMed]
- Guo, Z.Y.; Giambrone, J.J.; Dormitorio, T.V.; Wu, H. Influence of a reovirus-antibody complex vaccine on efficacy of Marek's disease vaccine administered in ovo. *Avian Dis.* **2003**, *47*, 1362–1367. Available online: <http://www.jstor.org/stable/1593177> (accessed on 15 August 2024). [CrossRef] [PubMed]
- Worthington, K.J.; Sargent, B.A.; Davelaar, F.G.; Jones, R.C. Immunity to avian pneumovirus infection in turkeys following in ovo vaccination with an attenuated vaccine. *Vaccine* **2003**, *21*, 1355–1362. [CrossRef]
- Hess, M.; Huggins, M.B.; Heincz, U. Hatchability, serology and virus excretion following in ovo vaccination of chickens with an avian metapneumovirus vaccine. *Avian Pathol.* **2004**, *33*, 576–580. [CrossRef]
- Astill, J.; Alkie, T.; Yitbarek, A.; Abdelaziz, K.T.; Bavananthasivam, J.; Nagy, J.J.; Petrik, É.; Sharif, S. Induction of immune response in chickens primed in ovo with an inactivated H9N2 avian influenza virus vaccine. *BMC Res. Notes* **2018**, *11*, 428. [CrossRef]
- García, C.; Soriano, J.M.; Cortés, V.; Sevilla-Navarro, S.; Marin, C.; Balaguer, J.L.; Catalá-Gregori, P. Monitoring serologic response to single in ovo vaccination with an immune complex vaccine against infectious bursal disease in broilers. *Poult. Sci.* **2021**, *100*, 100999. [CrossRef] [PubMed]
- Marcano, V.C.; Cardenas-Garcia, S.; Diel, D.G.; Antoniassi da Silva, L.H.; Gogal, R.M., Jr.; Miller, P.J.; Brown, C.C.; Butt, S.L.; Goraichuk, I.V.; Dimitrov, K.M.; et al. A novel recombinant Newcastle disease vaccine improves post- In ovo vaccination survival with sustained protection against virulent challenge. *Vaccines* **2021**, *9*, 953. [CrossRef]
- Noor, S.M.; Husband, A.J.; Widders, P.R. In ovo oral vaccination with *Campylobacter jejuni* establishes early development of intestinal immunity in chickens. *Br. Poult. Sci.* **1995**, *36*, 563–573. [CrossRef] [PubMed]
- Elliott, K.E.C.; Branton, S.L.; Evans, J.D.; Peebles, E.D. Evaluation of the potential influence of the disinfection cycle on the efficacy of strain F *Mycoplasma gallisepticum* vaccine administered by in ovo injection to layer hatching eggs. *J. Appl. Poult. Res.* **2020**, *29*, 673–683. [CrossRef]
- Alqhtani, A.H.; Fatemi, S.A.; Elliott, K.E.C.; Branton, S.L.; Evans, J.D.; Leigh, S.A.; Gerard, P.D.; Peebles, E.D. Effects of the In ovo vaccination of the ts-11 Strain of *Mycoplasma gallisepticum* in layer embryos and posthatch chicks. *Animals* **2022**, *12*, 1120. [CrossRef]
- Hornok, S.; Szell, Z.; Sreter, T.; Kovacs, A.; Varga, I. Influence of in ovo administered *Cryptosporidium baileyi* oocyst extract on the course of homologous infection. *Vet. Parasitol.* **2000**, *89*, 313–319. [CrossRef]

22. Sokale, A.O.; Williams, C.J.; Hoerr, F.J.; Collins, K.E.C.; Peebles, E.D. Effects of administration of an in ovo coccidiosis vaccine at different embryonic ages on vaccine cycling and performance of broiler chickens. *Poult. Sci.* **2021**, *100*, 100914. [[CrossRef](#)]
23. Zhang, J.; Cai, K.; Mishra, R.; Jha, R. In ovo supplementation of chitooligosaccharide and chlorella polysaccharide affects cecal microbial community, metabolic pathways, and fermentation metabolites in broiler chickens. *Poult. Sci.* **2020**, *99*, 4776–4785. [[CrossRef](#)] [[PubMed](#)]
24. Huang, K.J.; Li, C.H.; Tsai, P.K.; Lai, C.C.; Kuo, Y.R.; Hsieh, M.K.; Cheng, C.W. Electromagnetic force-driven needle-free in ovo injection device. *Vet. Sci.* **2022**, *9*, 147. [[CrossRef](#)]
25. Gildersleeve, R.P.; Hoyle, C.M.; Miles, A.M.; Murray, D.L.; Ricks, C.A.; Secrest, M.N.; Williams, C.J.; Womack, C.L. Developmental performance of an egg injection machine for administration of Marek's disease vaccine. *J. Appl. Poult. Res.* **1993**, *2*, 337–346. [[CrossRef](#)]
26. Sarma, G.; Greer, W.; Gildersleeve, R.P.; Murray, D.L.; Miles, A.M. Field safety and efficacy of in ovo administration of HVT + SB-1 bivalent Marek's disease vaccine in commercial broilers. *Avian Dis.* **1995**, *39*, 211–217. [[CrossRef](#)]
27. Sokale, A.O.; Williams, C.J.; Triplett, M.D.; Hoerr, F.J.; Peebles, E.D. Effects of stage of broiler embryo development on coccidiosis vaccine injection accuracy, and subsequent oocyst localization and hatchling quality. *Poult. Sci.* **2020**, *99*, 189–195. [[CrossRef](#)]
28. Sharma, J.M.; Lee, L.F.; Wakenell, P.S. Comparative viral, immunologic, and pathologic responses of chickens inoculated with herpesvirus of turkeys as embryos or at hatch. *Am. J. Vet. Res.* **1984**, *45*, 1619–1623. [[PubMed](#)]
29. Ricks, C.A.; Avakian, A.; Bryan, T.; Gildersleeve, R.; Haddad, E.; Llich, R.; King, S.; Murray, L.; Phelps, P.; Poston, R.; et al. In ovo vaccination technology. *Adv. Vet. Med.* **1999**, *41*, 495–515. [[PubMed](#)]
30. Sharma, J.M.; Tizard, I. Avian cellular immune effector mechanisms. *Avian Pathol.* **1984**, *13*, 357–376. [[CrossRef](#)] [[PubMed](#)]
31. Sharma, J.M. Delayed replication of Marek's disease virus following in ovo inoculation during the late stage of embryonal development. *Avian Dis.* **1987**, *31*, 567–570. [[CrossRef](#)] [[PubMed](#)]
32. Castañeda, C.D.; McDaniel, C.D.; Abdelhamed, H.; Karsi, A.; Kiess, A.S. Evaluating bacterial colonization of a developing broiler embryo after in ovo injection with a bioluminescent bacteria. *Poult. Sci.* **2019**, *98*, 2997–3006. [[CrossRef](#)] [[PubMed](#)]
33. Williams, C.J.; Hopkins, B.A. Field evaluation of the accuracy of vaccine deposition by two different commercially available in ovo injection systems. *Poult. Sci.* **2011**, *90*, 223–226. [[CrossRef](#)] [[PubMed](#)]
34. Peebles, E.D. In ovo applications in poultry: A review. *Poult. Sci.* **2018**, *97*, 2322–2338. [[CrossRef](#)]
35. Williams, C.J.; Zedek, A.S. Comparative field evaluations of in-ovo applied technology. *Poult. Sci.* **2010**, *89*, 189–193. [[CrossRef](#)] [[PubMed](#)]
36. Avakian, A. Understanding in ovo vaccination. *Int. Hatch. Pract.* **2006**, *20*, 15–17. Available online: <http://www.positiveaction.info/pdfs/articles/hp20.5p15.pdf> (accessed on 25 July 2024).
37. Tong, Q.; Romanini, C.E.; Exadaktylos, V.; Bahr, C.; Berckmans, D.; Bergoug, H.; Eterradossi, N.; Roulston, N.; Verhelst, R.; McGonnell, I.M.; et al. Embryonic development and the physiological factors that coordinate hatching in domestic chickens. *Poult. Sci.* **2013**, *92*, 620–662. [[CrossRef](#)]
38. Sokale, A.O.; Williams, C.J.; Cummings, T.S.; Gerard, P.D.; Bello, A.; Peebles, E.D. Effects of in ovo injection of different doses of coccidiosis vaccine and turn-out times on broiler performance. *Poult. Sci.* **2018**, *97*, 1891–1898. [[CrossRef](#)] [[PubMed](#)]
39. Vandeputte, J.; Martel, A.; Van Rysselberghe, N.; Antonissen, G.; Verlinden, M.; De Zutter, L.; Heyndrickx, M.; Haesebrouck, F.; Pasmans, F.; Garmyn, A. In ovo vaccination of broilers against *Campylobacter jejuni* using a bacterin and subunit vaccine. *Poult. Sci.* **2019**, *98*, 5999–6004. [[CrossRef](#)] [[PubMed](#)]
40. Sharma, J.M. Embryo vaccination with infectious bursal disease virus alone or in combination with Marek's disease vaccine. *Avian Dis.* **1985**, *29*, 1155–1169. [[CrossRef](#)]
41. Sharma, J.M. Embryo vaccination of specific pathogen free chickens with infectious bursal disease virus: Tissue distribution of the vaccine virus and protection of the hatched chicken against disease. *Avian Dis.* **1986**, *30*, 776–780. [[CrossRef](#)] [[PubMed](#)]
42. Wakenell, P.S.; Sharma, J.M. Chicken embryonal vaccination with avian infectious bronchitis virus. *Am. J. Vet. Res.* **1986**, *47*, 933–938. [[PubMed](#)]
43. Berchieri, A., Jr.; Bolis, D.A. Vacinações e aplicações de produtos intra-ovo. In *Manejo Da Incubação. Campina*; Macari, M., Gonzales, E., Eds.; FACTA: Tokyo, Japan, 2003; pp. 267–283.
44. Sharma, J.M.; Coulson, B.D.; Young, E. Effect of in vitro adaptation of MDV on pock induction on the chorioallantoic membrane of embryonated chicken eggs. *Infect. Immun.* **1976**, *13*, 292–295. [[CrossRef](#)] [[PubMed](#)]
45. Williams, C.J. In-ovo vaccination and chick quality. *Int. Hatch. Pract.* **2005**, *19*, 7–13. Available online: <http://www.positiveaction.info/pdfs/articles/hp19.2p7.pdf> (accessed on 18 August 2024).
46. Abudabos, A. The Effect of broiler breeder strain and parent flock age on hatchability and fertile hatchability. *Int. J. Poult. Sci.* **2010**, *9*, 231–235. [[CrossRef](#)]
47. Avakian, A.; Wakenell, P.S.; Bryan, T.; Schaeffer, J.L.; Williams, C.J.; Whitfill, C.E. In ovo administration of Marek's disease vaccine: Importance of vaccine deposition site in the fertile egg. In Proceedings of the 51st Western Poultry Disease Conference, Puerto Vallarta, México, 1–4 May 2002; Veterinary Software Publishing: O'Fallon, IL, USA, 2002; Volume 3.

48. Amarasinghe, G.K.; Ceballos, N.G.A.; Banyard, A.C.; Basler, C.F.; Bavari, S.; Bennett, A.J.; Blasdel, K.R.; Briese, T.; Bukreyev, A.; Cai, Y.; et al. Taxonomy of the order Mononegavirales: Update 2018. *Arch. Virol.* **2018**, *163*, 2283–2294. [[CrossRef](#)]
49. Perozo, F.; Marcano, R.; Afonso, C. Biological and phylogenetic characterization of a genotype VII Newcastle disease virus from Venezuela: Efficacy of field vaccination. *J. Clin. Microbiol.* **2012**, *50*, 1204–1208. [[CrossRef](#)]
50. Jaganathan, S.; Ooi, P.T.; Phang, L.Y.; Allaudin, Z.N.B.; Yip, L.S.; Choo, P.Y.; Lim, B.K.; Lemiere, S.; Audonnet, J.C. Observation of risk factors, clinical manifestations and genetic characterization of recent Newcastle disease virus outbreak in West Malaysia. *BMC Vet. Res.* **2015**, *11*, 219. [[CrossRef](#)] [[PubMed](#)]
51. Wajid, A.; Dimitrov, K.M.; Wasim, M.; Rehmani, S.F.; Basharat, A.; Bibi, T.; Arif, S.; Yaqub, T.; Tayyab, M.; Ababneh, M.; et al. Repeated isolation of virulent Newcastle disease viruses in poultry and captive non-poultry avian species in Pakistan from 2011 to 2016. *Prev. Vet. Med.* **2017**, *142*, 1–6. [[CrossRef](#)]
52. Absalon, A.E.; Cortés-Espinosa, D.V.; Lucio, E.; Miller, P.J.; Afonso, C.L. Epidemiology, control, and prevention of Newcastle disease in endemic regions: Latin America. *Trop. Anim. Health Prod.* **2019**, *51*, 1033–1048. [[CrossRef](#)]
53. Dimitrov, K.M.; Afonso, C.L.; Yu, Q.; Miller, P.L. Newcastle disease vaccines—A solved problem or a continuous challenge? *Vet. Microbiol.* **2017**, *206*, 126–136. [[CrossRef](#)]
54. Schijns, V.E.J.C.; van de Zande, S.; Lupiani, B.; Refy, S.M. Practical Aspects of Poultry Vaccination. In *Avian Immunology*; Schat, K.A., Kaspers, B., Kaiser, P., Eds.; Elsevier: Amsterdam, The Netherlands, 2013; pp. 345–362.
55. Gallili, G.E.; Ben-Nathan, D. Newcastle disease vaccines. *Biotechnol. Adv.* **1998**, *16*, 343–366. [[CrossRef](#)]
56. Jansen, T.; Hofmans, M.P.M.; Theelen, M.J.G.; Cshijns, V.E.J.C. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. *Vaccine* **2005**, *23*, 1053–1060. [[CrossRef](#)] [[PubMed](#)]
57. Giambrone, J.J.; Closser, J. Effect of breeder vaccination on immunization of progeny against Newcastle disease. *Avian Dis.* **1990**, *34*, 114–119. [[CrossRef](#)] [[PubMed](#)]
58. Ahmad, J.; Sharma, J.M. Evaluation of a modified-live virus vaccine administered in ovo to protect chickens against Newcastle disease. *Am. J. Vet. Res.* **1992**, *53*, 1999–2004. [[CrossRef](#)] [[PubMed](#)]
59. Mast, J.; Nanbru, C.; Decaesstecker, M.; Lambrecht, B.; Couvreur, B.; Meulemans, G.; van den Berg, T. Vaccination of chicken embryos with escape mutants of La Sota Newcastle disease virus induces a protective immune response. *Vaccine* **2006**, *24*, 1756–1765. [[CrossRef](#)] [[PubMed](#)]
60. Dilaveris, D.; Chen, C.; Kaiser, P.; Russel, P.H. The safety and immunogenicity of an in ovo vaccine against Newcastle disease virus differ between two lines of chicken. *Vaccine* **2007**, *25*, 3792–3799. [[CrossRef](#)] [[PubMed](#)]
61. Cardenas-Garcia, S.; Dunwoody, R.P.; Marcano, V.; Diel, D.G.; Williams, R.J.; Gogal, R.M., Jr.; Brown, C.C.; Miller, P.J.; Afonso, C.L. Effects of chicken interferon gamma on Newcastle disease virus vaccine immunogenicity. *PLoS ONE* **2016**, *11*, e0159153. [[CrossRef](#)] [[PubMed](#)]
62. Coletti, M.; Del Rossi, E.; Franciosini, M.P.; Passamonti, F.; Tacconi, G.; Marini, C. Efficacy and safety of an infectious bursal disease virus intermediate vaccine in ovo. *Avian Dis.* **2001**, *45*, 1036–1043. [[CrossRef](#)] [[PubMed](#)]
63. Dunon, D.; Courtois, D.; Vainio, O.; Six, A.; Chen, C.H.; Cooper, M.D.; Dangy, J.P.; Imhof, B.A. Ontogeny of the immune system: Gamma/delta and alpha/beta T cells migrate from thymus to the periphery in alternating waves. *J. Exp. Med.* **1997**, *186*, 977–988. [[CrossRef](#)] [[PubMed](#)]
64. Ohta, H.; Ezo, S.; Yamazaki, K.; Kawai, T.; Honda, T. Application of aluminum hydroxide for an in ovo live Newcastle disease vaccine. *Avian Dis.* **2009**, *53*, 392–395. [[CrossRef](#)]
65. Romanutti, C.; Keller, L.; Zanetti, F.A. Current status of virus-vectored vaccines against pathogens that affect poultry. *Vaccine* **2020**, *38*, 6990–7001. [[CrossRef](#)] [[PubMed](#)]
66. Hein, R.; Koopman, R.; Garcia, M.; Armour, N.; Dunn, J.R.; Barbosa, T.; Martinez, A. Review of poultry recombinant vector vaccines. *Avian Dis.* **2021**, *65*, 438–452. [[CrossRef](#)] [[PubMed](#)]
67. Rautenschlein, S.; Sharma, J.M.; Winslow, B.J.; McMillen, J.; Junker, D.; Cochran, M. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferon's as adjuvant. *Vaccine* **2000**, *18*, 426–433. [[CrossRef](#)]
68. Palya, V.; Kiss, I.; Tatár-Kis, T.; Mató, t.; Felföldi, B.; Gardin, Y. Advancement in vaccination against Newcastle disease: Recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions. *Avian Dis.* **2012**, *56*, 282–287. [[CrossRef](#)]
69. Esaki, M.; Godoy, A.; Rosenberger, J.K.; Rosenberger, S.C.; Gardin, Y.; Yasuda, A.; Dorsey, K.M. Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine. *Avian Dis.* **2013**, *57*, 750–755. [[CrossRef](#)] [[PubMed](#)]
70. Schat, K.A. *Back to the Past: Do Vector Vaccines Represent the Future?* Department of Microbiology and Immunology College of Veterinary Medicine, Cornell University: Ithaca, NY, USA, 2015; pp. 1–12.
71. Xu, Z.; Wei, W.; Gagneur, J.; Clauder-Münster, S.; Smolik, M.; Huber, W.; Steinmetz, L.M. Antisense expression increases gene expression variability and locus interdependency. *Mol. Syst. Biol.* **2011**, *7*, 468. [[CrossRef](#)]
72. Pelechano, V.; Steinmetz, L.M. Gene regulation by antisense transcription. *Nat. Rev. Genet.* **2013**, *14*, 880–893. [[CrossRef](#)]

73. Karaca, K.; Sharma, J.M.; Winslow, B.J.; Junker, D.E.; Reddy, S.; Cochran, M.; McMillen, J. Recombinant fowlpox viruses co-expressing chicken type I IFN and Newcastle disease virus HN and F genes: Influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses. *Vaccine* **1998**, *16*, 1496–1503. [[CrossRef](#)] [[PubMed](#)]
74. Ramp, K.; Topfstedt, E.; Wackerlin, R.; Hoper, D.; Ziller, M.; Mettenleiter, T.C.; Grund, C.; Romer-Oberdorfer, A. Pathogenicity and immunogenicity of different recombinant Newcastle disease virus clone 30 variants after in ovo vaccination. *Avian Dis.* **2012**, *56*, 208–217. [[CrossRef](#)]
75. Kapczynski, D.R.; Martin, A.; Haddad, E.E.; King, D.J. Protection from clinical disease against three highly virulent strains of Newcastle disease virus after in ovo application of an antibody-antigen complex vaccine in maternal antibody-positive chickens. *Avian Dis.* **2012**, *56*, 555–560. [[CrossRef](#)] [[PubMed](#)]
76. Jeurissen, S.H.; Janse, E.M.; Lehrbach, P.R.; Haddad, E.E.; Avakian, A.; Whitfill, C.E. The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease. *Immunology* **1998**, *95*, 494–500. [[CrossRef](#)] [[PubMed](#)]
77. Shirai, J.; Seki, R.; Kamimura, R.; Mitsubayashi, S. Effects of invert soap with 0.05% sodium hydroxide on infectious bursal disease virus. *Avian Dis.* **1994**, *38*, 240–243. [[CrossRef](#)] [[PubMed](#)]
78. Corley, M.M.; Giambrone, J.J.; Dormitorio, T.V. Detection of infectious bursal disease vaccine viruses in lymphoid tissues after in ovo vaccination of specific-pathogen-free embryos. *Avian Dis.* **2001**, *45*, 897–905. [[CrossRef](#)] [[PubMed](#)]
79. Kelemen, M.; Forgách, K.; Iván, J.; Palya, V.; Süveges, T.; Tóth, B.; Mészáros, J. Pathological and immunological study of an in ovo complex vaccine against infectious bursal disease. *Acta Vet. Hung.* **2000**, *48*, 443–454. [[CrossRef](#)] [[PubMed](#)]
80. de Wit, J.J.; Jorna, I.; Finger, A.; Loeb, V.; Dijkman, R.; Ashash, U.; Ifrah, M.; Raviv, Z. In ovo application of a live infectious bursal disease vaccine to commercial broilers confers proper immunity. *Avian Pathol.* **2021**, *50*, 531–539. [[CrossRef](#)] [[PubMed](#)]
81. Ashash, U.; Noach, C.; Perelman, B.; Costello, C.; Sansalone, P.; Brazil, T.; Raviv, Z. In ovo and day of hatch application of a live infectious bursal disease virus vaccine to commercial broilers. *Avian Dis.* **2019**, *63*, 713–720. [[CrossRef](#)] [[PubMed](#)]
82. Lara, L.J.C.; Michell, B.C.; Baião, N.C.; Resende, M.; Gomes, A.D.; Martins, N.R.S. Effect of maternally-derived antibodies on the performance and immunity of broilers induced by in ovo or post-hatching immunizations with a live vaccine against infectious bursal disease. *Braz. J. Poult. Sci.* **2009**, *11*, 57–63. [[CrossRef](#)]
83. Riaz, M.N.; Hussain, I.; Akhtar, M.; Rasool, M.H.; Mansoor, M.K.; Haq, S.E.U. Evaluation of in ovo vaccination against infectious bursal disease virus in commercial broilers in Pakistan. *Int. J. Agric. Biol.* **2004**, *6*, 984–986. Available online: https://www.fsublishers.org/published_papers/97468_pdf (accessed on 12 April 2024).
84. Rautenschlein, S.; Haase, C. Differences in the immunopathogenesis of infectious bursal disease virus (IBDV) following in ovo and post-hatch vaccination of chickens. *Vet. Immunol. Immunopathol.* **2005**, *106*, 139–150. [[CrossRef](#)] [[PubMed](#)]
85. Zaheer, I.; Chen, W.; Khan, A.; Elokil, A.; Saleemi, M.K.; Zaheer, T.; Khan, M.Z. Immunopathological comparison of in ovo and post-hatch vaccination techniques for infectious bursal disease vaccine in layer chicks. *Front. Vet. Sci.* **2022**, *9*, 947522. [[CrossRef](#)] [[PubMed](#)]
86. Fahey, K.J.; Crooks, J.K.; Fraser, R.A. Assessment by ELISA of passively acquired protection against infectious bursal disease virus in chickens. *Aust. Vet. J.* **1987**, *64*, 203–207. [[CrossRef](#)]
87. Giambrone, J.J.; Dormitorio, T.; Brown, T. Safety and efficacy of in ovo administration of infectious bursal disease viral vaccines. *Avian Dis.* **2001**, *45*, 144–148. [[CrossRef](#)] [[PubMed](#)]
88. McCarty, J.E.; Brown, T.P.; Giambrone, J.J. Delay of infectious bursal disease virus infection by in ovo vaccination of antibody-positive chicken eggs. *J. Appl. Poult. Res.* **2005**, *14*, 136–140. [[CrossRef](#)]
89. McCarty, J.; Newman, L.; Brown, T.P.; Giambrone, J. The effect of in ovo IBDV vaccination when administered in antibody positive and negative chickens. In Proceedings of the XIII Congress World Veterinary Poultry Association, Denver, CO, USA, 19–23 July 2003.
90. Corley, M.M.; Giambrone, J.J.; Dormitorio, T.V. Evaluation of the immune response and detection of infectious bursal disease viruses by reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay after in ovo vaccination of commercial broilers. *Avian Dis.* **2002**, *46*, 803–809. [[CrossRef](#)] [[PubMed](#)]
91. Park, J.H.; Sung, H.W.; Yoon, B.I.; Kwon, H.M. Protection of chicken against very virulent IBDV provided by in ovo priming with DNA vaccine and boosting with killed vaccine and the adjuvant effects of plasmid-encoded chicken interleukin-2 and interferon-gamma. *J. Vet. Sci.* **2009**, *10*, 131–139. [[CrossRef](#)]
92. Gagic, M.; St Hill, C.A.; Sharma, J.M. In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents. *Avian Dis.* **1999**, *43*, 293–301. [[CrossRef](#)] [[PubMed](#)]
93. Muller, H.; Mundt, E.; Eterradosi, N.; Rafiqul Islam, M. Current status of vaccines against infectious bursal disease. *Avian Pathol.* **2012**, *41*, 133–139. [[CrossRef](#)] [[PubMed](#)]
94. Davison, F. *The Importance of the Avian Immune System and its Unique Features: Embryonic (In Ovo) Vaccination*, 2nd ed.; Schat, K.A., Kaspers, B., Kaiser, P., Eds.; Elsevier Ltd.: San Diego, CA, USA, 2014.
95. Comte, S.; Borne, P. *Vacinas e Vacinação na Produção Avícola*; Ceva Santa Animale: São Paulo, Brazil, 2003; p. 140.

96. Zhang, Y.; Sharma, J.M. Early post-hatch protection against Marek's disease in chickens vaccinated in ovo with a CVI988 serotype 1 vaccine. *Avian Dis.* **2001**, *45*, 639–645. [[CrossRef](#)]
97. Tarpey, I.; van Loon, A.A.; de Haas, N.; Davis, P.J.; Orbell, S.; Cavanagh, D.; Britton, P.; Casais, R.; Sondermeijer, P.; Dundick, R. A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virus. *Vaccine* **2007**, *25*, 8529–8535. [[CrossRef](#)] [[PubMed](#)]
98. Reddy, S.K.; Sharma, J.M.; Ahmed, J.; Reddy, D.N.; McMillan, J.K.; Cook, S.M.; Wild, M.A.; Schwartz, R.D. Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific pathogen free chickens. *Vaccine* **1996**, *14*, 469–477. [[CrossRef](#)] [[PubMed](#)]
99. Davison, A.J.; Eberle, R.; Hayward, G.S.; McGeoch, D.J.; Minson, A.C.; Pellet, P.E.; Roizman, B.; Studdert, M.J.; Thiry, E. The order Herpesvirales. *Arch. Virol.* **2009**, *154*, 171–177. [[CrossRef](#)] [[PubMed](#)]
100. García, M.; Spatz, S.; Guy, J. Infectious Laryngotracheitis. In *Diseases of Poultry*, 13th ed.; Swayne, D.E., Glisson, J.R., McDougald, L.R., Nolan, L.K., Suarez, D.L., Nair, V.L., Eds.; Wiley-Blackwell: Ames, IA, USA, 2013; pp. 161–179.
101. Guy, J.; Garcia, M. Infectious Laryngotracheitis Virus. In *Diseases of Poultry*, 12th ed.; Saif, Y.M., Glisson, J.R., Fadly, A.M., McDougald, L.R., Nolan, L.K., Swayne, D.E., Eds.; Blackwell Publishing: Ames, AI, USA, 2008; pp. 137–152.
102. Gelenczei, E.F.; Marty, E.W. Studies on a tissue-culture modified infectious laryngotracheitis virus. *Avian Dis.* **1964**, *8*, 105–122. [[CrossRef](#)]
103. Fulton, R.M.; Schrader, D.L.; Will, M. Effect of route of vaccination on the prevention of infectious laryngotracheitis in commercial egg-laying chickens. *Avian Dis.* **2000**, *44*, 8–16. [[CrossRef](#)] [[PubMed](#)]
104. Han, M.G.; Kim, S.J. Efficacy of live virus vaccines against infectious laryngotracheitis assessed by polymerase chain reaction restriction fragment length polymorphism. *Avian Dis.* **2003**, *47*, 261–271. [[CrossRef](#)]
105. Rodríguez-Avila, A.; Oldoni, I.; Riblet, I.; Riblet, S.M.; García, M. Evaluation of the protection elicited by direct and indirect exposure to live attenuated infectious laryngotracheitis virus (ILTV) vaccines against a recent challenge strain from the United States. *Avian Pathol.* **2008**, *37*, 287–292. [[CrossRef](#)]
106. Davison, S.; Gingerich, E.; Casavant, N.S.; Eckroade, R.J. Evaluation of the efficacy of a live fowlpox-vectored infectious laryngotracheitis/avian encephalomyelitis vaccine against ILT viral challenge. *Avian Dis.* **2006**, *50*, 50–54. [[CrossRef](#)] [[PubMed](#)]
107. Vagnozzi, A.; Zavala, G.; Riblet, S.M.; Mundt, A.; García, M. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens. *Avian Pathol.* **2012**, *41*, 21–31. [[CrossRef](#)] [[PubMed](#)]
108. Maekawa, D.; Beltrán, G.; Riblet, S.M.; García, M. Protection efficacy of a recombinant herpesvirus of turkey vaccine against infectious laryngotracheitis virus administered in ovo to broilers at three standardized doses. *Avian Dis.* **2019**, *63*, 351–358. [[CrossRef](#)] [[PubMed](#)]
109. Johnson, D.I.; Vagnozzi, A.; Dorea, F.; Riblet, S.M.; Mundt, A.; Zavala, G.; García, M. Protection against infectious laryngotracheitis virus (ILTV) by in ovo vaccination by commercially available viral vector recombinant vaccines. *Avian Dis.* **2010**, *54*, 1251–1259. [[CrossRef](#)]
110. Williams, S.M.; Smith, J.A.; García, M.; Brinson, D.; Kiupel, M.; Hofacre, C. Severe histiolymphocytic and heterophilic bronchopneumonia as a reaction to in ovo fowlpox vaccination in broiler chicks. *Vet. Pathol.* **2010**, *47*, 177–180. [[CrossRef](#)]
111. Mashchenko, A.; Riblet, S.M.; Zavala, G.; García, M. In ovo vaccination of commercial broilers with a glycoprotein J gene-deleted strain of infectious laryngotracheitis virus. *Avian Dis.* **2013**, *57*, 523–531. [[CrossRef](#)]
112. Thapa, S.; Cader, M.S.A.; Murugananthan, K.; Nagy, E.; Sharif, S.; Czub, M.; Abdul-Careem, M.F. In ovo delivery of CpG DNA reduces avian infectious laryngotracheitis virus induced mortality and morbidity. *Viruses* **2015**, *7*, 1832–1852. [[CrossRef](#)] [[PubMed](#)]
113. Gimeno, I.M.; Cortes, A.L.; Guy, J.S.; Turpin, E.; Williams, C. Replication of recombinant herpesvirus of turkey expressing genes of infectious laryngotracheitis virus in specific pathogen free and broiler chickens following in ovo and subcutaneous vaccination. *Avian Pathol.* **2011**, *40*, 395–403. [[CrossRef](#)]
114. Cavanaugh, D.; Madwort, K.; Welchman, D.; Britton, P.; Gough, R.E. Coronaviruses from pheasants (*Phasianus colchicus*) are genetically closely related to coronaviruses of domestic fowl (infectious bronchitis virus) and turkeys. *Avian Pathol.* **2002**, *31*, 81–93. [[CrossRef](#)] [[PubMed](#)]
115. Cavanagh, D.; Naqi, S. Infectious Bronchitis. In *Diseases of Poultry*, 10th ed.; Calnek, B.W., Barnes, H.J., McDougald, L.R., Saif, Y.M., Eds.; Iowa State University Press: Ames, IA, USA, 1997; pp. 511–526.
116. Ignjatovic, J.; Gould, G.; Sapats, S. Isolation of a variant infectious bronchitis virus in Australia that further illustrates diversity among emerging strains. *Arch. Virol.* **2003**, *151*, 1567–1585. [[CrossRef](#)] [[PubMed](#)]
117. Babapoor, S.; Almeida, D.O.; Fabis, J.J.; Helal, Z.H.; Wang, X.; Girshick, T.; Khan, M.I. Protective effect of in ovo vaccination with IBV-spike-recombinant DNA and chicken interferon as an adjuvant. *Int. J. Poult. Sci.* **2009**, *8*, 1034–1041. [[CrossRef](#)]
118. Wakenell, P.S.; Sharma, J.M.; Slocombe, R.F. Embryo vaccination of chickens with infectious bronchitis virus: Histologic and ultrastructural lesion response and immunologic response to vaccination. *Avian Dis.* **1995**, *39*, 752–765. [[CrossRef](#)]

119. Khan, M.I.; Fabis, J.J. In ovo vaccination for IBV, using DNA vaccine. A preliminary study. In Proceedings of the 139th Annual American Veterinary Medical Association Convention and Meeting, Nashville, KY, USA, 14–17 July 2002; p. 73.
120. Kapczynski, D.R.; Hilt, D.A.; Shapiro, D.; Sellers, H.S.; Jackwood, M.W. Protection of chickens from infectious bronchitis by in ovo and intramuscular vaccination with a DNA vaccine expressing the S1 glycoprotein. *Avian Dis.* **2003**, *47*, 272–285. [[CrossRef](#)] [[PubMed](#)]
121. Fabis, J.J.; Khan, M.I. In vivo expression of IBV-S gene in chicks inoculated with recombinant DNA vaccine in ovo. In Proceedings of the IV Symposium on Avian Corona and Pneumovirus Infections, Rauschholzhhausen, Germany, 20–23 June 2004; pp. 232–236.
122. Chew, P.H.; Wakenell, P.S.; Farver, T.B. Pathogenicity of attenuated infectious bronchitis viruses for oviducts of chickens exposed in ovo. *Avian Dis.* **1997**, *41*, 598–603. [[CrossRef](#)]
123. Lee, C.W.; Brown, C.; Jackwood, M.W. Tissue distribution of avian infectious bronchitis virus following in ovo inoculation of chicken embryos examined by in situ hybridization with antisense digoxigenin-labeled universal riboprobe. *J. Vet. Diagn. Investig.* **2002**, *14*, 377–381. [[CrossRef](#)] [[PubMed](#)]
124. Avakian, A.P.; Wakenell, P.S.; Grosse, D.; Whitfill, C.E.; Link, D. Protective immunity to infectious bronchitis in broilers vaccinated against Marek's disease either in ovo or at hatch and against infectious bronchitis at hatch. *Avian Dis.* **2000**, *44*, 536–544. [[CrossRef](#)]
125. Tunio, M.T.; Abro, S.H.; Rind, R.; Wagan, R.; Hashmi, H.A. In ovo-vaccination of chicken embryos with infectious bronchitis virus vaccine. *Agric. Trop. Subtrop.* **2010**, *43*, 222–226. Available online: <https://agris.fao.org/agris-search/search.do?recordID=CZ2011000238> (accessed on 18 April 2024).
126. Wang, X.; Schnitzlein, W.M.; Tripathy, D.N.; Girshick, T.; Khan, M.I. Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus. *Avian Dis.* **2002**, *46*, 831–838. [[CrossRef](#)]
127. Johnson, M.A.; Pooley, C.; Ignjatovic, J.; Tyack, S.G. A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus. *Vaccine* **2003**, *21*, 2730–2736. [[CrossRef](#)] [[PubMed](#)]
128. De Silva Senapathi, U.; Aboelkhair, M.; Puro, K.; Ali, M.; Amarasinghe, A.; Abdul-Cader, M.S.; Van Marle, G.; Czub, M.; Abdul-Careem, M.F. In ovo delivered toll-like receptor 7 ligand, resiquimod enhances host responses against infectious bronchitis corona virus (IBV) infection. *Vaccines* **2020**, *8*, 186. [[CrossRef](#)] [[PubMed](#)]
129. Nagy, A.; Mettenleiter, T.C.; Abdelwhab, E.M. A brief summary of the epidemiology and genetic relatedness of avian influenza H9N2 virus in birds and mammals in the Middle East and North Africa. *Epidemiol. Infect.* **2017**, *145*, 3320–3333. [[CrossRef](#)]
130. Sun, Y.; Pu, J.; Fan, L.; Sun, H.; Wang, J.; Zhang, Y.; Liu, L.; Liu, J. Evaluation of the protective efficacy of a commercial vaccine against different antigenic groups of H9N2 influenza viruses in chickens. *Vet. Microbiol.* **2012**, *156*, 193–199. [[CrossRef](#)]
131. Stone, H.; Mitchell, B.; Brugh, M. In ovo vaccination of chicken embryos with experimental Newcastle disease and avian influenza oil emulsion vaccines. *Avian Dis.* **1997**, *41*, 856–863. [[CrossRef](#)]
132. Toro, H.; Tang, D.C.; Suarez, D.L.; Sylte, M.J.; Pfeifer, J.; Van Kampen, K.R. Protective avian influenza in ovo vaccination with non-replicating human adeno- virus vector. *Vaccine* **2007**, *25*, 2886–2891. [[CrossRef](#)]
133. Toro, H.; Tang, D.C. Protection of chickens against avian influenza with nonreplicating adenovirus-vectored vaccine. *Poult. Sci.* **2009**, *88*, 867–871. [[CrossRef](#)]
134. Mesonero, A.; Suarez, D.L.; van Santen, E.; Tang, D.C.; Toro, H. Avian influenza in ovo vaccination with replication defective recombinant adenovirus in chickens: Vaccine potency, antibody persistence, and maternal antibody transfer. *Avian Dis.* **2011**, *55*, 285–292. [[CrossRef](#)] [[PubMed](#)]
135. Cai, Y.; Song, H.; Ye, J.; Shao, H.; Padmanabhan, R.; Sutton, T.C.; Perez, D.R. Improved hatchability and efficient protection after in ovo vaccination with live attenuated H7N2 and H9N2 avian influenza viruses. *Viol. J.* **2011**, *8*, 31. [[CrossRef](#)] [[PubMed](#)]
136. Steel, J.; Burmakina, S.V.; Thomas, C.; Spackman, E.; García-Sastre, A.; Swayne, D.E.; Palese, P.A. A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. *Vaccine* **2008**, *26*, 522–531. [[CrossRef](#)] [[PubMed](#)]
137. Rafique, S.; Siddique, N.; Qayyum, M.; Abbas, M.A.; Ali, A.; Yasmeen, S.; Naeem, K. In ovo vaccination against avian influenza virus subtype H9N2. *Pak. Vet. J.* **2015**, *35*, 299–302. Available online: <https://agris.fao.org/agris-search/search.do?recordID=PK2017000161> (accessed on 16 March 2024).
138. Dar, A.; Tikoo, S.; Potter, A.; Babiuk, L.A.; Townsend, H.; Gerds, V.; Mutwiri, G. CpG-ODNs induced changes in cytokine/chemokines genes expression associated with suppression of infectious bronchitis virus replication in chicken lungs. *Vet. Immunol. Immunopathol.* **2014**, *160*, 209–217. [[CrossRef](#)] [[PubMed](#)]
139. Barjesteh, N.; Brisbin, J.T.; Behboudi, S.; Nagy, É.; Sharif, S. Induction of antiviral responses against avian influenza virus in embryonated chicken eggs with Toll-like receptor ligands. *Viral Immunol.* **2015**, *28*, 192–200. [[CrossRef](#)]
140. Tarpey, I.; Huggins, M.B. Onset of immunity following in ovo delivery of avian metapneumovirus vaccines. *Vet. Microbiol.* **2007**, *124*, 134–139. [[CrossRef](#)] [[PubMed](#)]
141. Cha, R.M.; Khatri, M.; Mutnal, M.; Sharma, J.M. Pathogenic and immunogenic responses in turkeys following in ovo exposure to avian metapneumovirus subtype C. *Vet. Immunol. Immunopathol.* **2011**, *140*, 30–36. [[CrossRef](#)]
142. Levisohn, S.; Kleven, S.H. Avian mycoplasmosis (*Mycoplasma gallisepticum*). *Rev. Sci. Tech.* **2000**, *19*, 425–442. [[CrossRef](#)] [[PubMed](#)]

143. Kleven, S.H. Mycoplasmas in the etiology of multifactorial respiratory disease. *Poult. Sci.* **1998**, *77*, 1146–1149. [[CrossRef](#)] [[PubMed](#)]
144. Elliott, K.E.C.; Branton, S.L.; Evans, J.D.; Peebles, E.D. Early post-hatch survival and humoral immune response of layer chickens when in ovo vaccinated with strain F *Mycoplasma gallisepticum*. *Poult. Sci.* **2018**, *97*, 3860–3869. [[CrossRef](#)] [[PubMed](#)]
145. Kleven, S.H. Changing expectations in the control of *Mycoplasma gallisepticum*. *Acta. Vet. Hung.* **1997**, *45*, 299–305. [[PubMed](#)]
146. Evans, J.D.; Leigh, S.A.; Branton, S.L.; Collier, S.D.; Pharr, G.T.; Bearson, S.M.D. *Mycoplasma gallisepticum*: Current and developing means to control the avian pathogen. *J. Appl. Poult. Res.* **2005**, *14*, 757–763. [[CrossRef](#)]
147. Ferguson-Noel, N.; Cookson, K.; Laibinis, V.A.; Kleven, S.H. The efficacy of three commercial *Mycoplasma gallisepticum* vaccines in laying hens. *Avian Dis.* **2012**, *56*, 272–275. [[CrossRef](#)] [[PubMed](#)]
148. Elliott, K.E.C.; Branton, S.L.; Evans, J.D.; Gerard, P.D.; Peebles, E.D. Layer chicken embryo survival to hatch when administered an in ovo vaccination of strain F *Mycoplasma gallisepticum* and locations of bacteria prevalence in the newly hatched chick. *Poult. Sci.* **2017**, *96*, 3879–3884. [[CrossRef](#)] [[PubMed](#)]
149. Elliott, K.E.C.; Branton, S.L.; Evans, J.D.; Peebles, E.D. Occurrence of horizontal transmission in layer chickens after administration of in ovo strain F *Mycoplasma gallisepticum* vaccine. *Poult. Sci.* **2019**, *98*, 4492–4497. [[CrossRef](#)] [[PubMed](#)]
150. Elliott, K.E.C.; Branton, S.L.; Evans, J.D.; Magee, C.L.; Peebles, E.D. Onset of the humoral immune response of layer chicks vaccinated in ovo with strain F *Mycoplasma gallisepticum* vaccine and evidence of male-biased mortality. *Poult. Sci.* **2022**, *101*, 101761. [[CrossRef](#)]
151. McDougald, L.R.; Fitz-coy, S.H. Coccidiosis. In *Diseases of Poultry*, 12th ed.; Saif, Y.M., Fadley, A.M., Glisson, J.R., McDougald, L.R., Nolan, L.K., Swayne, D.E., Eds.; Wiley-Blackwell Publishing: Ames, IA, USA, 2008; pp. 1067–1080.
152. Price, K.R. Use of live vaccines for coccidiosis control in replacement layer pullets. *J. Appl. Poult. Res.* **2012**, *21*, 679–692. [[CrossRef](#)]
153. Moore, R.J. Necrotic enteritis predisposing factors in broiler chickens. *Avian Pathol.* **2016**, *45*, 275–281. [[CrossRef](#)]
154. Jenkins, M.C.; Parker, C.; Ritter, D. *Eimeria* oocyst concentrations and species composition in litter from commercial broiler farms during anticoccidial drug or live *Eimeria* oocyst vaccine control programs. *Avian Dis.* **2017**, *61*, 214–220. [[CrossRef](#)]
155. Parent, E.; Fernandez, D.; Boulianne, M. The use of a live non-attenuated coccidiosis vaccine modifies *Eimeria* spp. excretion in commercial antibiotic-free broiler chicken flocks compared to conventional shuttle anticoccidial programs. *Poult. Sci.* **2018**, *97*, 2740–2744. [[CrossRef](#)]
156. Price, K.R.; Hafeez, M.A.; Bulfon, J.; Barta, J.R. Live *Eimeria* vaccination success in the face of artificial non-uniform vaccine administration in conventionally reared pullets. *Avian Pathol.* **2016**, *45*, 82–93. [[CrossRef](#)] [[PubMed](#)]
157. Watkins, K.L.; Brooks, M.A.; Jeffers, T.K.; Phelps, P.V.; Ricks, C.A. The effect of in ovo oocyst or sporocyst inoculation on response to subsequent coccidial challenge. *Poult. Sci.* **1995**, *74*, 1597–1602. [[CrossRef](#)] [[PubMed](#)]
158. Mathis, G.; Schaeffer, J.; Cookson, K.; Dickson, J.; LaVorgna, M.; Waldrip, D. Effect of lasalocid or salinomycin administration on performance and immunity following coccidia vaccination of commercial broilers. *J. Appl. Poult. Res.* **2014**, *23*, 577–585. [[CrossRef](#)]
159. Weber, F.H.; Evans, N.A. Immunization of broiler chicks by in ovo injection of *Eimeria tenella* sporozoites, sporocysts, or oocysts. *Poult. Sci.* **2003**, *82*, 1701–1707. [[CrossRef](#)] [[PubMed](#)]
160. Weber, F.H.; Genteman, K.C.; LeMay, M.A.; Lewis, D.O.; Evans, N.A. Immunization of broiler chicks by in ovo injection of infective stages of *Eimeria*. *Poult. Sci.* **2004**, *83*, 392–399. [[CrossRef](#)]
161. Weber, F.H.; Farrand, M.; LeMay, M.A.; Lewis, D.O.; Genteman, K.C.; Evans, N.A. Movement of oocysts within chicken embryos after in ovo vaccination with *Eimeria maxima*. In Proceedings of the VIIIth International Coccidiosis Conference, Palm Cove, Australia, 9–13 July 2001; Australian Society for Parasitology: Queensland, Australia, 2002; p. 184.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.